Literature DB >> 86704

Propranolol binding to serum orosomucoid.

B J Scott, A R Bradwell, R E Schneider, H Bishop.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 86704     DOI: 10.1016/s0140-6736(79)91415-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Drug binding in the undernourished: a study of the binding of propranolol to alpha 1-acid glycoprotein.

Authors:  V Jagadeesan; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 2.  Disease-induced changes in the plasma binding of basic drugs.

Authors:  K M Piafsky
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

3.  Influence of age on serum protein binding of propranolol.

Authors:  R Bendayan; J A Pieper; R B Stewart; G J Caranasos
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Authors:  R E Schneider; H Bishop
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

5.  Effect of heparin on serum binding of propranolol in the acute phase of myocardial infarction.

Authors:  G Sager; V Hansteen; I Aakesson; S Jacobsen
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

6.  Changes in blood chemistry in hypertensive patients during propranolol therapy.

Authors:  F Andreasen; P Jakobsen; H J Kornerup; E B Pedersen; O L Pedersen; J Weeke
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Drug binding in sera deficient in lipoproteins, albumin or orosomucoid.

Authors:  E Pike; P Kierulf; B Skuterud; J E Bredesen; P K Lunde
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

8.  Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum of healthy and diseased humans.

Authors:  O Teirlynck; F M Belpaire; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.